Funding for this research was provided by:
the National Key Research and Development Program of China (2017YFC1103900)
the National Key Research and Development Program of China (2018YFB1105600)
Received: 1 February 2019
Revised: 3 April 2019
Accepted: 29 April 2019
First Online: 21 May 2019
Ethics approval and consent to participate
: The protocol of the study was approved by the Ethics Committee of Ren Ji Hospital, Shanghai Jiao Tong University. Researchers adhered to the principles of the Helsinki Declaration throughout the study and written informed consent was obtained from the patients. The study was registered at ExternalRef removed (NCT02162693).
: Not applicable.
: Chengxiang Dai, Suke Li, and Li Zhang are current employees and stock option holders of the Cellular Biomedicine Group (Nasdaq: CBMG). The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.